nach oben

Erschienen in:

01.08.2012 | PRECLINICAL STUDIES

Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo

verfasst von: Juan R. Rodrigues, Jaime Charris, Rosa Ferrer, Neira Gamboa, Jorge Ángel, Bianca Nitzsche, Michael Hoepfner, Michael Lein, Klaus Jung, Claudia Abramjuk

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

Quinolines and acrylates are chemical compounds which were previously described as potential antitumor agents. In this study, a series of seven new quinolinyl acrylate derivatives were synthesized and evaluated against human prostate cancer cells PC-3 and LNCaP in vitro and in vivo. The most effective compound (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4 hydroxyphenyl) acrylate reduced the viability in both cell lines in a time- and dose-dependent manner. Inhibitory effects were also observed on the adhesion, migration, and invasion of the prostate cancer cells as well as on the neoangiogenesis, clonogenic and MMP-9 activity. The effect in vivo was studied in PC-3 xenografts in nude mice. The results were concordant with the in vitro effects and showed decreased tumor growth in treated animals compared to controls. The study suggests the multi-target efficacy of the quinolinyl derivate against human prostate cancer cells and supports its potential therapeutic usefulness.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Canc J Clin 61:69–90CrossRef

Lukevics E, Abele E, Arsenyan P, Abele R, Rubina K, Shestakova I, Domracheva I, Vologdina V (2002) Synthesis and cytotoxicity of silicon containing pyridine and quinoline sulfides. Met Based Drugs 9:45–51CrossRefPubMed

Mol W, Matyja M, Filip B, Wietrzyk J, Boryczka S (2008) Synthesis and antiproliferative activity in vitro of novel (2-butynyl)thioquinolines. Bioorg Med Chem 16:8136–8141CrossRefPubMed

Hranjec M, Grdisa M, Pavelic K, Boykin DW, Karminski-Zamola G (2003) Synthesis and antitumor evaluation of some new substituted amidino-benzimidazolyl-furyl-phenyl-acrylates and naphtho[2,1-b]furan-carboxylates. Farmaco 58:1319–1324CrossRefPubMed

Hranjec M, Starcevic K, Piantanida I, Kralj M, Marjanovic M, Hasani M, Westman G, Karminski-Zamola G (2008) Synthesis, antitumor evaluation and DNA binding studies of novel amidino-benzimidazolyl substituted derivatives of furyl-phenyl- and thienyl-phenyl-acrylates, naphthofurans and naphthothiophenes. Eur J Med Chem 43:2877–2890CrossRefPubMed

Yang L, Zeng W, Li D, Zhou R (2009) Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncol Rep 22:121–126CrossRefPubMed

Burg-Roderfeld M, Roderfeld M, Wagner S, Henkel C, Grotzinger J, Roeb E (2007) MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol 30:985–992PubMed

Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML (2002) Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Canc Inst 94:17–25CrossRef

Stetler-Stevenson WG, Yu AE (2001) Proteases in invasion: matrix metalloproteinases. Semin Canc Biol 11:143–152CrossRef

10.

Chen MH, Cui SX, Cheng YN, Sun LR, Li QB, Xu WF, Ward SG, Tang W, Qu XJ (2008) Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity. Anticancer Drugs 19:957–965CrossRefPubMed

11.

Rodrigues J, Abramjuk C, Vasquez L, Gamboa N, Dominguez J, Nitzsche B, Hopfner M, Georgieva R, Baumler H, Stephan C, Jung K, Lein M, Rabien A (2011) New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer. Pharm Res 28:907–919CrossRefPubMed

12.

Ruiz Y, Rodrigues J, Arvelo F, Usubillaga A, Monsalve M, Diez N, Galindo-Castro I (2008) Cytotoxic and apoptosis-inducing effect of ent-15-oxo-kaur-16-en-19-oic acid, a derivative of grandiflorolic acid from Espeletia schultzii. Phytochemistry 69:432–438CrossRefPubMed

13.

Atienza JM, Zhu J, Wang X, Xu X, Abassi Y (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 10:795–805CrossRefPubMed

14.

Rodriguez LG, Wu X, Guan JL (2005) Wound-healing assay. Meth Mol Biol 294:23–29

15.

Qu X, Yuan Y, Xu W, Chen M, Cui S, Meng H, Li Y, Makuuchi M, Nakata M, Tang W (2006) Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. Anticancer Res 26:3573–3578PubMed

16.

Nitzsche B, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M, Zakrzewicz A, Hoffmann B, Hopfner M (2010) Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Canc 103:18–28CrossRef

17.

Powell AA, Akare S, Qi W, Herzer P, Jean-Louis S, Feldman RA, Martinez JD (2006) Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity. BMC Canc 6:219CrossRef

18.

Feldman JP, Goldwasser R, Mark S, Schwartz J, Orion I (2009) A mathematical model for tumor volume evaluation using two-dimensions. J Appl Quant Methods 4:455–462

19.

Gurovic MS, Lanza AM, Adanez MC, Omana MC, Gomez IG, Murray AP, Lopez PS (2011) Cytotoxic effects induced by combination of heliantriol B2 and dequalinium against human leukemic cell lines. Phytother Res 25:603–610CrossRefPubMed

20.

Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008) Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Canc Res 68:1777–1785CrossRef

21.

Freedman VH, Shin SI (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3:355–359CrossRefPubMed

22.

Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF (2001) Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22:1765–1773CrossRefPubMed

23.

Khodursky AB, Zechiedrich EL, Cozzarelli NR (1995) Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 92:11801–11805CrossRefPubMed

24.

Dominguez JN, Leon C, Rodrigues J, Gamboa de Dominguez N, Gut J, Rosenthal PJ (2005) Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J Med Chem 48:3654–3658CrossRefPubMed

25.

Seck M, Desrivot J, Bories C, Loiseau P, Franck X, Hocquemiller R, Figadere B, Peyrat JF, Provot O, Brion JD, Alami M (2005) Antileishmanial activity of five 2- or 3- quinolines by enyne group. Dakar Med 50:172–175PubMed

26.

Ferrer R, Lobo G, Gambo N, Rodrigues J, Abramjuk C, Jung K, Lein M, Charris JE (2009) Synthesis of 7-chloroquinolinyl-4-aminophenylchalcones: potential antimalarial and anticancer agents. Sci Pharm 77:725–741CrossRef

27.

Gao M, Wang M, Miller KD, Hutchins GD, Zheng QH (2010) Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. Bioorg Med Chem 18:2099–2106CrossRefPubMed

28.

Beauchard A, Jaunet A, Murillo L, Baldeyrou B, Lansiaux A, Cherouvrier JR, Domon L, Picot L, Bailly C, Besson T, Thiery V (2009) Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives. Eur J Med Chem 44:3858–3865CrossRefPubMed

29.

Takeuchi Y, Oda T, Chang MR, Okamoto Y, Ono J, Oda Y, Harada K, Hashigaki K, Yamato M (1997) Synthesis and antitumor activity of fused quinoline derivatives. IV. Novel 11-aminoindolo[3,2-b]quinolines. Chem Pharm Bull (Tokyo) 45:406–411CrossRef

30.

Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T (2010) Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 9:107CrossRefPubMed

31.

Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE (2009) Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Canc 101:1233–1240CrossRef

32.

Chen Y, Chen S, Lu X, Cheng H, Ou Y, Cheng H, Zhou GC (2009) Synthesis, discovery and preliminary SAR study of benzofuran derivatives as angiogenesis inhibitors. Bioorg Med Chem Lett 19:1851–1854CrossRefPubMed

33.

Chien CM, Yang SH, Lin KL, Chen YL, Chang LS, Lin SR (2008) Novel indoloquinoline derivative, IQDMA, suppresses STAT5 phosphorylation and induces apoptosis in HL-60 cells. Chem Biol Interact 176:40–47CrossRefPubMed

34.

Mabeta P, Auer R, Mphahlele MJ (2009) Evaluation of the antiangiogenic effects of 2-aryl-3-bromoquinolin-4(1H)-ones and a NCH3-4-oxo derivative. Biol Pharm Bull 32:937–940CrossRefPubMed

35.

Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918–921CrossRefPubMed

36.

Chodniewicz D, Klemke RL (2004) Guiding cell migration through directed extension and stabilization of pseudopodia. Exp Cell Res 301:31–37CrossRefPubMed

37.

Pepper MS (1997) Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605–619CrossRefPubMed

38.

Shi J, Xiao Z, Ihnat MA, Kamat C, Pandit B, Hu Z, Li PK (2003) Structure-activity relationships studies of the anti-angiogenic activities of linomide. Bioorg Med Chem Lett 13:1187–1189CrossRefPubMed

39.

Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411–424CrossRefPubMed

40.

Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, Collan Y, Pyrhonen S (2010) MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Canc Investig 28:38–43CrossRef

41.

Mira E, Lacalle RA, Buesa JM, de Buitrago GG, Jimenez-Baranda S, Gomez-Mouton C, Martinez A, Manes S (2004) Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 117:1847–1857CrossRefPubMed

42.

Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ (2002) Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Canc Inst 94:1134–1142CrossRef

43.

Cifone MA, Fidler IJ (1980) Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 77:1039–1043CrossRefPubMed

Titel: Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo
verfasst von: Juan R. Rodrigues
Jaime Charris
Rosa Ferrer
Neira Gamboa
Jorge Ángel
Bianca Nitzsche
Michael Hoepfner
Michael Lein
Klaus Jung
Claudia Abramjuk
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-011-9716-3

Springer Medizin

Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie